Latest Breaking News On - மரகதம் ஆரோக்கியம் மருந்துகள் - Page 1 : comparemela.com
Otonomy : Appoints Jill Broadfoot to Board of Directors (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Synthetic Cannabinoids Market to Grow at a CAGR of 16% Through 2029 – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
This series of 13 videos, designed for healthcare professionals, focuses on diagnosing MS, its psychological impact, managing symptoms, and treatments. Quality-of-life issues, fatigue, and patient support networks also will be discussed. I hope general neurologists will watch it, not just MS specialists, as many general neurologists seem out of touch with the ins and outs of diagnosing and treating multiple sclerosis. Just ask their patients.
NeurologyLive and the Consortium of Multiple Sclerosis Centers (CMSC) have launched a new video series called Cure Connections, designed to provide healthcare professionals with expert news and insights about multiple sclerosis (MS).
“These past several months our partnership with the CMSC has escalated to producing and disseminating extremely important education for neurology professionals everywhere,” Mike Hennessy Jr., president and CEO of MJH Life Sciences, NeurologyLive‘s parent company, said in a press release.
Emerald Health Preparing for Phase 2 Trial of EHP-101 for Relapsing MS 4.3 (12)
Emerald Health Pharmaceuticals (EHP) is preparing for an international Phase 2 clinical trial testing EHP-101 for the treatment of multiple sclerosis (MS).
The study will take place in about 20 locations in the U.S. and Australia, and is expected to include approximately 50 patients with relapsing forms of MS relapsing-remitting and relapsing secondary progressive MS. Enrollment is expected to begin later this year.
“The initiation of this MS Phase 2 study is another important milestone for our lead product candidate, EHP-101,” Joachim Schupp, MD, EHP’s chief medical officer, said in a press release.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel .
Emerald Health PharmaceuticalsFebruary 9, 2021 GMT
Data published in peer-reviewed journal,
Molecular and Cellular Neuroscience
show neuroprotective and neurogenic activity of proprietary product candidate, EHP-102
SAN DIEGO, CA, Feb. 09, 2021 (GLOBE NEWSWIRE) Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat neurodegenerative and other diseases with unmet medical needs, has published a scientific article in the peer-reviewed journal,
Molecular and Cellular Neuroscience, highlighting data supporting the potential of EHP’s drug product candidate, EHP-102, to treat Parkinson’s disease (PD). EHP-102 employs a multi-modal mechanism of action, which may offer a new path to better treatment outcomes.
vimarsana © 2020. All Rights Reserved.